Is Genes & Development a Good Journal? The CSHL Gene Regulation Flagship
Genes & Development is the CSHL Press journal for gene regulation with IF 7.5. Here's when your paper fits, how it compares to Molecular Cell, EMBO Journal, and Development, and what editors reward.
Senior Researcher, Oncology & Cell Biology
Author context
Specializes in manuscript preparation and peer review strategy for oncology and cell biology, with deep experience evaluating submissions to Nature Medicine, JCO, Cancer Cell, and Cell-family journals.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
How to read Genes & Development as a target
This page should help you decide whether Genes & Development belongs on the shortlist, not just whether it sounds impressive.
Question | Quick read |
|---|---|
Best for | Genes & Development publishes biologically significant research in molecular biology, molecular genetics,. |
Editors prioritize | A biologically significant question with broad consequence |
Think twice if | Submitting a technically strong but too-local mechanism story |
Typical article types | Research Papers, Research Communications, Resource and methodology papers |
Quick answer: Genes & Development (IF 7.5, JCR 2024) is a respected Cold Spring Harbor Laboratory Press journal focused on gene regulation and developmental biology. It is a good journal for mechanistic papers that explain how genes are regulated. It is a weak journal for descriptive gene expression studies or narrow pathway observations without conceptual reach.
The Editorial Distinction
Genes & Development was launched in 1987 and built its reputation publishing the molecular biology of gene regulation: transcription, chromatin, epigenetics, RNA processing, and developmental gene control. The CSHL Press imprint carries weight in the gene regulation community.
The editorial question is: does this paper explain a regulation mechanism that teaches the community something durable?
The journal rewards conceptual clarity over data volume. A paper that reveals a new principle of transcriptional control with clean, interpretable experiments fits perfectly. A paper that generates extensive omics data showing that gene X is dysregulated in condition Y, without explaining the regulatory mechanism, does not.
The Numbers
Metric | Value |
|---|---|
Impact Factor (JCR 2024) | 7.5 |
5-Year IF | ~10.2 |
Publisher | Cold Spring Harbor Laboratory Press |
Quartile | Q1 in Developmental Biology, Q1 in Genetics |
Acceptance rate | ~15-20% |
APC | Free (subscription) with delayed OA (6 months) |
Scope | Gene regulation, chromatin, transcription, epigenetics, developmental biology |
How Genes & Development Compares
Journal | IF (2024) | Acceptance | Best For |
|---|---|---|---|
Genes & Development | 7.5 | ~15-20% | Gene regulation mechanisms, CSHL Press |
Molecular Cell | 16.6 | ~8-10% | Broad molecular mechanisms, Cell Press |
EMBO Journal | 8.3 | ~10-15% | Broad molecular biology, EMBO |
Development | 3.7 | ~25-30% | Developmental biology, Company of Biologists |
Genes & Development vs Molecular Cell: Molecular Cell (IF 16.6) is a tier above and covers broader molecular biology. For the strongest gene regulation papers that have molecular-cell-level impact, Molecular Cell is the reach target. Genes & Development is for papers that are mechanistically excellent but not necessarily at the Cell Press threshold. The two journals share readership overlap in gene regulation, but Molecular Cell's scope extends into structural biology, signaling, and metabolism.
Genes & Development vs EMBO Journal: EMBO Journal (IF 9.5) covers broader molecular biology with a European editorial base. It's slightly higher impact and broader in scope. For gene regulation papers that also touch signaling, cell biology, or disease mechanisms, EMBO may be the better fit. For pure gene regulation (transcription, chromatin, epigenetic mechanisms) Genes & Development is the more focused home.
Genes & Development vs Development: Development (IF 3.7) is the Company of Biologists journal for developmental biology. Its IF is substantially lower, but it's the core society journal for developmental biologists. If the paper is primarily about an embryological or organ development question where the gene regulation is secondary, Development may be the better audience. If the paper is primarily about the regulation mechanism that happens to be studied in a developmental system, Genes & Development is the fit.
The Declining IF Question
Authors should be honest about this: Genes & Development's IF has declined from around 12 a decade ago to 7.5 today. This doesn't mean the journal is weak. It means the molecular biology publishing landscape has shifted, with Cell Press and Nature journals absorbing many of the highest-impact gene regulation papers. Genes & Development remains respected, but it no longer competes in the same IF bracket as Molecular Cell or Nature Structural & Molecular Biology.
For career purposes, this matters. A Genes & Development paper still signals quality in gene regulation. But at institutions where IF numbers are counted during tenure review, the gap between Genes & Development (IF 7.5) and Molecular Cell (IF 16.6) or Nature Genetics (IF 29.0) is visible.
Submit If
- The paper explains a gene regulation mechanism with conceptual clarity and clean experiments
- The insight matters beyond one narrow pathway, it teaches something about how regulation works
- The evidence package is mature and review-ready, not preliminary
- Gene regulation is the core contribution, not a secondary finding
Readiness check
Run the scan while the topic is in front of you.
See score, top issues, and journal-fit signals before you submit.
Think Twice If
- The paper is competitive for Molecular Cell or EMBO Journal, try there first for the IF advantage
- The study is descriptive gene expression profiling without mechanistic explanation
- The contribution is a narrow pathway observation in one model system without broader regulatory insight
- Development (for developmental biology) or Nucleic Acids Research (for chromatin/transcription) would give the paper a more engaged specialist readership
- IF matters for your career timeline and 7.5 falls below your institutional threshold
Frequently Asked Questions
Is Genes & Development free to publish?
Yes under the subscription model. The journal offers delayed open access (free after 6 months). There's no APC for standard publication, which is a financial advantage over many OA genomics journals.
What happened to the journal's impact?
The IF decline reflects competition from Cell Press (Molecular Cell, Cell Reports), Nature journals (Nature Genetics, Nature Structural & Molecular Biology), and eLife. The biological sciences journal landscape has consolidated around a few high-IF brands. Genes & Development publishes the same quality of gene regulation work but competes for the highest-impact papers with journals that have broader scopes and higher visibility.
Does CSHL Press reputation still carry weight?
Yes, particularly among gene regulation specialists and the molecular biology community trained at Cold Spring Harbor courses and meetings. The CSHL Press brand signals rigor and mechanistic depth. But brand recognition varies, younger researchers and those outside the gene regulation community may be less familiar with the journal.
Are there specific areas where Genes & Development is strongest?
Transcriptional regulation, chromatin biology, and epigenetic mechanisms remain the journal's core strengths. Papers on non-coding RNA regulation, developmental gene networks, and cell fate decisions also publish well. The journal is less strong for structural biology or biochemistry without a clear gene regulation story.
Before submitting, a Genes & Development scope and readiness check can help you assess whether your gene regulation paper fits Genes & Development or should aim for Molecular Cell or EMBO Journal first.
Before you submit
A Genes & Development submission readiness check identifies the specific framing and scope issues that trigger desk rejection before you submit.
Frequently asked questions
Genes & Development has a 2024 JCR impact factor of 7.5 with a 5-year IF of approximately 10.2. It is ranked Q1 in Developmental Biology and Genetics. The journal has been published by Cold Spring Harbor Laboratory Press since 1987.
Yes, but with context. Genes & Development's IF has decreased from ~12 a decade ago to ~7.5 today, reflecting shifts in the molecular biology publishing landscape. The journal remains respected for gene regulation and developmental mechanism, but it no longer competes at the same IF tier as Molecular Cell, with JIF 14.5. For the right mechanistic paper, it's still a strong home.
Gene regulation mechanisms: transcription, chromatin, RNA processing, epigenetics, and developmental gene control. The journal wants papers that explain HOW genes are regulated, not just what happens when a gene is knocked out. Mechanistic depth is the editorial priority.
Molecular Cell, with JIF 14.5, is a tier above in impact metrics and covers broader molecular biology. Genes & Development, with JIF 7.5, is more focused on gene regulation and development. For papers competitive at Molecular Cell, try there first. Genes & Development is the natural home for strong gene regulation work that doesn't need the Cell Press umbrella.
Sources
- Genes & Development about the journal, Cold Spring Harbor Laboratory Press.
- Genes & Development instructions to authors, Cold Spring Harbor Laboratory Press.
- Clarivate Journal Citation Reports (JCR 2024, released June 2025).
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Same journal, next question
- Genes & Development Submission Guide: What to Prepare Before You Submit
- How to Avoid Desk Rejection at Genes & Development (2026)
- Genes & Development Review Time: What Authors Can Actually Expect
- Genes & Development Impact Factor 2026: 7.7 - Small Journal, Outsized Reputation
- Genes & Development Submission Process: What Happens and What Editors Judge First
Compare alternatives
Supporting reads
Conversion step
Choose the next useful decision step first.
Use the scan once the manuscript and target journal are concrete enough to evaluate.